Morning or afternoon? new study tests best time for bladder cancer drugs

NCT ID NCT07346053

Not yet recruiting Symptom relief Sponsor: Guliz Ozgun Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving standard bladder cancer drugs in the morning or afternoon changes how well they work and how many side effects they cause. About 224 adults with advanced bladder cancer will be randomly assigned to receive their treatment either before 11:30 a.m. or after 1:30 p.m. Researchers will track tumor response and survival over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin and pembrolizumab (EV/P)
What this could lead to: If timing matters, this could make existing treatments more effective and less toxic without new drugs.
What could go wrong: This is a Phase 3 trial, but it only tests timing, not a new therapy. Results may show no difference or be hard to apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder cancer urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BLADDER CANCER

Contacts and locations

Locations

BC Cancer - Abbotsford

Abbotsford British Columbia, British Columbia, V2S 0C2, Canada
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)

Kelowna, British Columbia, V1Y 5L3, Canada
BC Cancer - Surrey

Surrey, British Columbia, V3V 1Z2, Canada
BC Cancer - Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
BC Cancer - Victoria

Victoria, British Columbia, V8R 6V5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.